Innate immunity cell activation in virologically suppressed HIV-infected maraviroc-treated patients.
This is a cross-sectional, case-control study analyzing the effect of antiretroviral therapy (ART) including or not maraviroc, on circulating monocytes and natural killer cells. Sixty-eight HIV-positive patients virologically suppressed receiving ART at least 6 months were subdivided as receiving (group 1) or not (group 2) maraviroc in their ART. Frequency of monocytes and natural killer cells, as well as their activation markers, were studied. Modulation of innate immune cells may be differently affected by combined ART.
aInfectious Diseases Department, Sanremo Hospital, Sanremo bCenter of Excellence for Biomedical Research (CEBR), University of Genoa cInfectious Diseases Department, IRCCS San Martino Hospital dDIMES Department of Experimental Medicine eDepartment of Informatics, Bioengineering, Robotic and System Engineering (DIBRIS) fSection of Biostatistics, Department of Health Sciences (DISSAL), University of Genoa gInfectious Diseases Department, Galliera Hospital, Genoa hInfectious Diseases Department, SS. Antonio, Biagio, Cesare Arrigo Hospital, Alessandria iInfectious Diseases Department, Amedeo di Savoia Hospital, Turin jDISSAL kDepartment of Internal Medicine (DIMI), University of Genoa, Genoa, Italy.
Chiara
C
Dentone
Antonio
A
Di Biagio
Alessia
A
Parodi
Federica
F
Bozzano
Paolo
P
Fraccaro
Alessio
A
Signori
Giovanni
G
Cenderello
Eugenio
E
Mantia
Giancarlo
G
Orofino
Andrea
A
De Maria
Gilberto
G
Filaci
Daniela
D
Fenoglio
D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D015703:Antigens, CD / Q000032:analysis; D015415:Biomarkers / Q000032:analysis; D016022:Case-Control Studies; D003430:Cross-Sectional Studies; D003510:Cyclohexanes / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology*; D006680:HLA Antigens / Q000032:analysis; D006801:Humans; D007694:Killer Cells, Natural / Q000737:chemistry / Q000276:immunology*; D008297:Male; D000077592:Maraviroc; D008875:Middle Aged; D009000:Monocytes / Q000737:chemistry / Q000276:immunology*; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*
D044966:Anti-Retroviral Agents; D015703:Antigens, CD; D015415:Biomarkers; D003510:Cyclohexanes; D006680:HLA Antigens; D014230:Triazoles; D000077592:Maraviroc